1. Implementation of a Digital Disease Management Platform for Heart Failure: AMAZE.
- Author
-
Paruchuri K, Bernardo R, Haidermota S, Lannery K, Finneran P, Wong M, Sanborn T, Joice M, Boyle-Kelly J, Silacci S, Hornsby W, Linganathan K, Olufade T, Januzzi JL Jr, and Natarajan P
- Abstract
Competing Interests: Disclosures KP reports grant support from Genentech and Allelica, unrelated to this work. KL and TO are employees of AstraZeneca. JJ is a trustee of the American College of Cardiology, a Director at Imbria Pharmaceuticals and Jana Care, has received grant support from Abbott, Applied Therapeutics, HeartFlow, Innolife, and Roche Diagnostics, consulting income from Abbott, AstraZeneca, Bayer, Beckman, Boehringer-Ingelheim, Janssen, Novartis, Merck, Quidel and Roche Diagnostics and participates in clinical endpoint committees/data-safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Pfizer, and Takeda. PN reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in Preciseli and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work except for AstraZeneca as noted below. All other authors declare that they have no competing interests.
- Published
- 2024
- Full Text
- View/download PDF